Journal of Clinical and Experimental Ophthalmology
Open Access

Agard E

Publications

• Letter to Editor
  Effect of Intravitreal Dexamethasone Implant (Ozurdex^®) in the Glycemic Control of Patients with Diabetic Macular Edema
  Author(s): Agard E, Le Berre JP, El Chehab H, Malclès A, Russo A, Mounier C and Dot C Agard E, Le Berre JP, El Chehab H, Malclès A, Russo A, Mounier C and Dot C
  
  Purpose: To evaluate the effect of intravitreal dexamethasone implant (Ozurdex®) in the glycemic control of patients with diabetic macular edema. Methods: Ten patients with diabetic macular edema received an intravitreal injection (IVI) of dexamethasone implant (DEX implant, Ozurdex®). Glycated haemoglobin (HbA1C) is analyzed before and three months after IVI. The real-time glycemic readings are provided by a new medical device (Dexcom G4®; Dexcom, Fr). The primary outcome analysis was the comparison of HbA1C test before and after IVI. Results: The mean HbA1C level was 7.46 ± 0.70% before IVI and 7.60 ± 1.30% after IVI. No significant difference was found for the percentage of time spent above the target, within the target, and below the target. Di.. View More»
  DOI: 10.4172/2155-9570.1000568

  Abstract PDF

Relevant Topics